E
AKBA icon

Ergoteles’s Akebia Therapeutics AKBA Stock Holding History

Ergoteles’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-97,521
Closed -$56.3K – 1210
2022
Q4 		$56.3K Sell
97,521
-67,716
-41% -$21.2K ﹤0.01% 1282
2022
Q3 		$52K Sell
165,237
-683,763
-81% -$268K ﹤0.01% 1438
2022
Q2 		$300K Buy
+849,000
New +$356K 0.01% 1102

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ergoteles's AKBA Position: Q1 2023 in Review

Ergoteles sold out of Akebia Therapeutics (AKBA) in Q1 2023, closing a stake of 97,521 shares — an estimated $56.3K sold.

Ergoteles first reported a position in AKBA in Q2 2022 and held it in 3 quarters. The position peaked at $300K in Q2 2022. 65 funds tracked by Wall St. Rank hold AKBA as of Q1 2023.

  • Ergoteles reported no remaining Akebia Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 97,521 Akebia Therapeutics shares in Q1 2023, an estimated $56.3K.
  • Ergoteles first reported a position in Akebia Therapeutics in Q2 2022 and held it in 3 quarters.
  • Ergoteles's Akebia Therapeutics position peaked at $300K in Q2 2022.
  • 65 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.